OBJECTIVES: Weight of glaucoma as a cause of blindness remains significant. Thus the problem of drug supply of glaucoma patients is actual for health care system of Russian Federation. We conducted 3 pharmacoeconomic studies for treatment of open-angle glaucoma for each antiglaucoma drugs groups (eye-drops): prostaglandin analogues (Travatan (travoprost), Xalatan (latanoprost); carbonic anhydrase inhibitors (CAI) (Azopt (brinzolamide), Dorzopt and Trusopt (dorzolamide)) and combined drugs of prostoglandin analogues and beta-blocker (Duotrav (travoprost+timolol) and Xalacom (latanoprost+timolol) to find optimal antiglaucoma drugs from pharmacoeconomics perspective in Russia. METHODS: Cost-efficacy and budget impact analysis were used, direct costs were considered.  RESULTS: In the first study we found that Travatan is dominant in comparison with Xalatan and provide lower cost per effective glaucoma control per year per patient – cost-efficacy ratio (CER) for Travatan was 18,092 RUB and for Xalatan 19,270 RUB. Furthermore Travatan to Xalatan provided 1091 RUB cost saving per patient per year. The second pharmacoeconomic study of CAIs has shown that Azopt had benefits in terms of cost-efficacy analysis to Dorzopt and Trusopt: CER (cost of achieving annual control for glaucoma by 1% patients) for Azopt it was 304 RUB, for Dorzopt – 342 RUB, for Trusopt – 382 RUB. The third study has shown advantage of Duotrav in comparison with Xalacom in terms of cost-efficacy analysis and budget impact analysis. Duotrav had lower CER (cost per 1% of patients, for whom treatment remains effective for 5 years) 1345 RUB in comparison with 1463 RUB for Xalacom and provided 1721 RUB of cost-saving (discounted at 3%).  CONCLUSIONS: The results of conducted pharmacoeconomic studies show that Travatan, Azopt and Duotrav are dominated drugs among alternatives in health care system of Russian Federation for treatment of open-angle glaucoma from perspective of pharmacoeconomic analysis.